Trial Profile
Study of the Effects of Obeticholic Acid on Farnesoid X Receptor Expression in Jejunum and on Gut Microbiota in Morbidly Obese Patients and Healthy Volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- Acronyms OCAPUSH
- 22 Aug 2020 Planned End Date changed from 1 Oct 2019 to 1 Jun 2021.
- 22 Aug 2020 Planned primary completion date changed from 1 Oct 2019 to 1 Dec 2020.
- 26 Apr 2018 Planned End Date changed from 1 Oct 2017 to 1 Oct 2019.